Trelegy Ellipta (Fluticasone Furoate, Umeclidinium Bromide, and Vilanterol Trifenatate Inhalation Powder) is a triple-combination therapy medication containing fluticasone furoate (an inhaled corticosteroid), umeclidinium bromide (an anticholinergic agent), and vilanterol (a long-acting β₂-adrenergic agonist). It is primarily used for the maintenance treatment of chronic obstructive pulmonary disease (COPD) and asthma in adults.
What Are the Side Effects of Trelegy Ellipta (Fluticasone Furoate, Umeclidinium Bromide, and Vilanterol Trifenatate Inhalation Powder)?
In Patients with COPD
Respiratory system: Upper respiratory tract infection (8%), pneumonia (8%), bronchitis.
Infectious diseases: Oropharyngeal candidiasis.
Nervous system: Headache (4%).
Musculoskeletal system: Back pain (4%), arthralgia.
Digestive system: Dysgeusia (2%), constipation, diarrhea, gastroenteritis.
In Patients with Asthma
Pharyngitis/rhinopharyngitis (15-17%).
Upper respiratory tract infection/viral upper respiratory tract infection (5-7%).
Bronchitis (4-5%), respiratory tract infection (2-4%), sinusitis (2-3%).
Urinary tract infection (2%), rhinitis, influenza.
Headache (5-9%), back pain (2-3%).
Severe Side Effects of Trelegy Ellipta (Fluticasone Furoate, Umeclidinium Bromide, and Vilanterol Trifenatate Inhalation Powder) Requiring High Alert
Cardiovascular System Risks
Trelegy Ellipta may cause clinically significant cardiovascular reactions.
These include increased pulse rate, elevated blood pressure, and arrhythmias (supraventricular tachycardia, premature contractions).
Electrocardiogram (ECG) changes (prolonged QTc interval, flattened T waves, ST-segment depression) may also occur.
Severe Allergic Reactions
These include anaphylactic shock, angioedema, rash, and urticaria.
Contraindication: Patients with a severe allergy to milk proteins or any component of the medication.
Opportunistic Infections
Pneumonia risk: The incidence of pneumonia is significantly increased in COPD patients using this medication.
Oropharyngeal candidiasis: May require local or systemic antifungal treatment.
Tuberculosis, as well as fungal/bacterial/viral infections, may be exacerbated.
Precautions for Using Trelegy Ellipta (Fluticasone Furoate, Umeclidinium Bromide, and Vilanterol Trifenatate Inhalation Powder)
Contraindicated Scenarios
Status asthmaticus or acute exacerbations of COPD/asthma that require intensive treatment.
Not to be used for the relief of acute bronchospasm.
Hepatic Impairment
Patients with moderate to severe hepatic impairment require dosage adjustment (systemic exposure to fluticasone furoate may increase by 3-fold).
Monitoring for corticosteroid-related side effects is necessary.
